Akoustis Technologies Inc AKTS

$0.04 0.00 (-9.05%)

Valuation

Market cap
5,751,000
Revenue TTM
$27,380,000
Net income TTM
$-167,950,000
PE ratio
0.00
Forward PE
—
Profit margin
-613.40%
Debt to equity
0.00

Trading

Volume
118,703,398
Avg volume
26,170,799
Day's range
$0.03 – $0.04
Shares out
154,591,000
Stochastic %K
6%
Beta
1.91
Analysts
Sell
Price target
$1.00

Price

Company profile

Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or...

Show more

Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors. It has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is headquartered in Boston, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
617 461 4023
Website
https://www.aktisoncology.com
Address
17 Drydock Avenue, Suite 17-401, Boston, United States

Latest news

Stocktwits

herdimmunity Sep 25, 3:22 PM
$AKTS buy
0 replies
RadioIsotope25 Sep 20, 12:00 AM
Perspective Therapeutics - 1773753 Looks better than $AKTS at 20% of valuation $CATX $IOVA https://event.webcasts.com/viewer/event.jsp?ei=1773753&tp_key=c315a3b312
0 replies
RadioIsotope25 Sep 17, 3:03 PM
Morgan Stanley - Perspective Therapeutics - 1773753 $CATX $AKTS $IOVA https://event.webcasts.com/viewer/event.jsp?ei=1773753&tp_key=c315a3b312
0 replies
MysticChartReaderIQ69 Sep 8, 6:12 PM
$AKTS decent amount of competition in the space
0 replies
RadioIsotope25 Sep 7, 1:30 PM
PERSPECTIVE THERAPEUTICS COPORATE VIDEO - SNMMI 2026 Annual Meeting $CATX $AKTS $PYXS $SLS https://snmmi26.smallworldlabs.com/video/72
0 replies
RadioIsotope25 Sep 1, 4:23 PM
CATX 13F Hedge Fund & Institutional Ownership | HedgeFollow $CATX $IOVA $IMNM $PYXS $AKTS https://hedgefollow.com/stocks/CATX
0 replies
RadioIsotope25 Aug 31, 1:38 AM
Shorts can get buried on ESMO data since EV is so low and cash is so high. ORR of 43% is very high and they keep hiring like mad they could be ready to show 50%+ with no renal toxicity could quadruple soon. They are giving an oral presentation which walk reserves for good data and science. The best of the best are long. CATX $IOVA $IBRX $IMNM $AKTS
0 replies
RadioIsotope25 Aug 28, 5:30 PM
$IOVA $IMNM $IBRX $AKTS Might have a IOVA move in October
0 replies